semaglutide
Wegovy Approved to Treat MASH With Moderate to Advanced Fibrosis
The FDA has approved semaglutide with diet and exercise for the treatment of MASH with moderate to advanced ...
AUGUST 20, 2025
Insurance Restrictions, Low Reimbursement Hitting Pharmacies on GLP-1s
Despite increasing demand for GLP-1 drugs, these medications are often excluded from coverage in employer health ...
MAY 27, 2025
FDA Declares End to Semaglutide Shortage; Clock Ticking on Compounded Versions
In the wake of the FDA’s Feb. 21, 2025 announcement declaring an end to the semaglutide shortage, ...
FEBRUARY 24, 2025
‘A War Brewing’ Over GLP-1 Agonist Production
Are glucagon-like peptide-1 agonist drugs such as semaglutide and tirzepatide too complex for 503A and 503B ...
NOVEMBER 21, 2024
Can Machine Learning Predict GLP-1 Responders?
Machine learning tools can sift through genetic profiles to predict which patients with obesity will best respond ...
NOVEMBER 20, 2024
How a GLP-1 ‘Shadow System’ Puts Patients’ Safety at Risk
Dozens of unscrupulous web-based sellers of glucagon-like peptide-1 agonist drugs are evading FDA scrutiny and ...
NOVEMBER 7, 2024
'Tail Period' for Compounders Could Ease Weight-Loss Rx Shortages
Compounder should be allowed to produce products beyond the FDA’s current hard compounding cut-off. The ...
OCTOBER 10, 2024
Machine Learning Can Predict Best Responders to GLP-1s
Machine learning tools can sift through genetic profiles to predict which patients with obesity will best respond ...
SEPTEMBER 21, 2024
Report: GLP-1 Adherence Rates Lower Than Expected
Glucagon-like peptide-1 agonists have exploded in use and popularity to treat obesity in nondiabetic patients since ...
JULY 25, 2024
GLP-1RA Use Increases Gastric Food Retention Post-Endoscopy—But Fasting Mitigates This
Although patients appear more likely to retain stomach contents during endoscopic procedures, this risk may ...
MAY 29, 2024
Report: GLP-1 Adherence Rates Lower Than Expected
Although more than 90% of patients adhered to GLP-1 agonists through the end of clinical trials, new data suggest ...
MAY 23, 2024
FDA Approves Wegovy for Cardiovascular Risk Reduction
The FDA approved semaglutide (Wegovy, Novo Nordisk) for lowering cardiovascular death, heart attack and stroke risk ...
MARCH 8, 2024
